Shares in Stentys rise 6 percent after the medical technology company says it has recruited its first patient in a pivotal study for its self-apposing stent, an important step towards applying for marketing approval in the United States.
"We are convinced that the stock should very quickly recover thanks notably to a particularly rich newsflow," Gilbert Dupont analysts write in a note, referring to partnerships outside Europe, upcoming clinical trial results and sharp growth expected in the coming quarters.
Stentys shares are up 6.18 percent at 0836 GMT at 9.97 euros, the biggest risers on France's CAC mid and small index.
The shares are still down 22 percent since the start of the year - hit by a widening operating loss in 2012, governance changes and the sale of shares by the company's founder - valuing Stentys at 114 million euros.
To see a statement, please click
Reuters messaging rm://alice.cannet.thomsonreuters.com@reuters.net
